News & blog

Tackling drug resistance: UK-China funding competition announced

Business Support News

cw655

A new competition for 2018 will make up to £10 million available to UK organisations to work with Chinese partners.
Next year will see a collaborative competition launched between the UK and China to develop solutions that address the threat of antimicrobial resistance.
Innovate UK is to invest up to £10 million in UK businesses, on behalf of the Department of Health. The Chinese Ministry of Science and Technology (MoST) will invest up to 60 million RMB to fund the Chinese partners.
The aim is to support novel projects that neither country would be able to conduct within the same timeframe without the other’s expertise. These should develop new products or services against antimicrobial resistance (AMR). Where appropriate, they should include clinical evaluation.
Addressing the threat of drug resistance
It has been estimated that failure to tackle drug-resistant infections will lead to at least 10 million extra deaths a year by 2050. This would cost the global economy up to $100 trillion USD.
A substantial research and innovation effort is needed to address the emergence and spread of antimicrobial resistance, and to speed up the development of new antimicrobials and supporting technologies.
What is in scope
When the call opens we will be looking for projects that:

  • explore opportunities from traditional Chinese medicine for the treatment or prevention of infectious diseases in humans or animals
  • advance the discovery of new agents to prevent or treat drug-resistant bacterial infection in humans or livestock. New agents could include small molecule drugs, vaccines, antibodies or other biological products
  • identify new agents that will increase the feed energy conversion in livestock. This should be done without use of antibiotics or hormones
  • maximise the clinical utility of current antibiotics. The aim is to improve the prognosis of patients with extensively drug-resistant infections
  • improve capabilities for the diagnosis, treatment selection and surveillance of bacterial infections and antibacterial resistance

All projects must comply with Official Development Assistance (ODA) criteria. Read more

Share this